Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.3 ILa | +7.45% | +7.45% | -54.71% |
Sales 2024 * | 14.36M 5.26B | Sales 2025 * | 27.77M 10.16B | Capitalization | 56.61M 20.72B |
---|---|---|---|---|---|
Net income 2024 * | -47M -17.2B | Net income 2025 * | -36M -13.18B | EV / Sales 2024 * | 3.94 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.04 x |
P/E ratio 2024 * |
-2.36
x | P/E ratio 2025 * |
-
| Employees | 79 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.64% |
Latest transcript on BioLineRx Ltd.
1 day | +7.45% | ||
1 week | +7.45% | ||
Current month | -1.70% | ||
1 month | +3.59% | ||
3 months | -42.14% | ||
6 months | -55.06% | ||
Current year | -54.71% |
Managers | Title | Age | Since |
---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 63 | 09-05-23 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 08-12-31 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 17-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 14-02-23 |
Avraham Molcho
BRD | Director/Board Member | 66 | 09-12-31 |
Aharon Schwartz
CHM | Chairman | 80 | 03-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-26 | 17.3 | +7.45% | 1,238,299 |
24-05-23 | 16.1 | +2.55% | 457,377 |
24-05-22 | 15.7 | -2.48% | 348,381 |
24-05-21 | 16.1 | +1.26% | 299,682 |
24-05-20 | 15.9 | -1.24% | 154,201 |
Delayed Quote TEL AVIV STOCK EXCHANGE, May 26, 2024 at 08:49 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-54.71% | 52.69M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- BLRX Stock